摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-cyclobutyl-5-methyl-1,3-thiazol-2-amine | 1698908-50-7

中文名称
——
中文别名
——
英文名称
4-cyclobutyl-5-methyl-1,3-thiazol-2-amine
英文别名
——
4-cyclobutyl-5-methyl-1,3-thiazol-2-amine化学式
CAS
1698908-50-7
化学式
C8H12N2S
mdl
——
分子量
168.263
InChiKey
WGGSVUFHXVAWIF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    321.0±11.0 °C(Predicted)
  • 密度:
    1.233±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    67.2
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF
    申请人:Genentech, Inc.
    公开号:US20160222033A1
    公开(公告)日:2016-08-04
    The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    本发明涉及某些噻唑嘧啶酮化合物、包含该类化合物的制药组合物以及使用该类化合物的治疗方法。
  • Thiazolopyrimidinones and methods of use thereof
    申请人:Genentech, Inc.
    公开号:US10647731B2
    公开(公告)日:2020-05-12
    The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    本发明涉及某些噻唑嘧啶酮化合物、包含此类化合物的药物组合物以及使用此类化合物进行治疗的方法。
  • Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design
    作者:Matthew Volgraf、Benjamin D. Sellers、Yu Jiang、Guosheng Wu、Cuong Q. Ly、Elisia Villemure、Richard M. Pastor、Po-wai Yuen、Aijun Lu、Xifeng Luo、Mingcui Liu、Shun Zhang、Liang Sun、Yuhong Fu、Patrick J. Lupardus、Heidi J.A. Wallweber、Bianca M. Liederer、Gauri Deshmukh、Emile Plise、Suzanne Tay、Paul Reynen、James Herrington、Amy Gustafson、Yichin Liu、Akim Dirksen、Matthias G. A. Dietz、Yanzhou Liu、Tzu-Ming Wang、Jesse E. Hanson、David Hackos、Kimberly Scearce-Levie、Jacob B. Schwarz
    DOI:10.1021/acs.jmedchem.5b02010
    日期:2016.3.24
    The N-methyl-D-aspartate receptor (NMDAR) is a Na+ and Ca2+ permeable ionotropic glutamate receptor that is activated by the coagonists glycine and glutamate. NMDARs are critical to synaptic signaling and plasticity, and their dysfunction has been implicated in a number of neurological disorders, including schizophrenia, depression, and Alzheimer's disease. Herein we describe the discovery of potent GluN2A-selective NMDAR positive allosteric modulators (PAMs) starting from a high-throughput screening hit. Using structure-based design, we sought to increase potency at the GluN2A subtype, while improving selectivity against related amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). The structure activity relationship of channel deactivation kinetics was studied using a combination of electrophysiology and protein crystallography. Effective incorporation of these strategies resulted in the discovery of GNE-0723 (46), a highly potent and brain penetrant GluN2A-selective NMDAR PAM suitable for in vivo characterization.
  • THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY
    申请人:F. Hoffmann-La Roche AG
    公开号:EP3055315B1
    公开(公告)日:2018-07-25
  • US9988400B2
    申请人:——
    公开号:US9988400B2
    公开(公告)日:2018-06-05
查看更多